KALVISTA PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.57 USD | -2.61% |
|
-7.45% | -5.63% |
Valuation
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 396.7 | 194.7 | 607 | 312.4 | 291.5 | 501.2 | - | - |
| Enterprise Value (EV) 1 | 364.7 | 127 | 358 | 146.2 | 142.1 | 282.9 | 396.5 | 501.2 |
| P/E ratio | -16.7 x | -6.65 x | -10.3 x | -3.79 x | -2.56 x | -3.91 x | -4.92 x | -23.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.6 x | 15.3 x | - | - | - | - | 33.5 x | 4.24 x |
| EV / Revenue | 22.6 x | 10 x | - | - | - | - | 26.5 x | 4.24 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | -4.52 x | -7.29 x | -1.85 x | -1.86 x | -2.05 x | -3.78 x | -14.1 x |
| FCF Yield | - | -22.1% | -13.7% | -54.1% | -53.8% | -48.8% | -26.5% | -7.08% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,247 | 17,846 | 24,308 | 24,543 | 34,169 | 42,188 | - | - |
| Reference price 2 | 23.00 | 10.91 | 24.97 | 12.73 | 8.530 | 11.88 | 11.88 | 11.88 |
| Announcement Date | 7/15/19 | 6/29/20 | 7/13/21 | 7/7/22 | 7/7/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16.13 | 12.69 | - | - | - | - | 14.95 | 118.3 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -29.82 | -40.53 | -57.92 | -96.61 | -110.9 | -126.1 | -116.9 | -33.51 |
| Operating Margin | -184.91% | -319.41% | - | - | - | - | -782.24% | -28.32% |
| Earnings before Tax (EBT) 1 | -20.69 | -29.24 | -46.24 | -82.34 | -92.91 | -113.6 | -107.4 | -24.41 |
| Net income 1 | -20.82 | -29.12 | -46.24 | -82.34 | -92.91 | -114 | -111.2 | -25.81 |
| Net margin | -129.08% | -229.44% | - | - | - | - | -743.81% | -21.82% |
| EPS 2 | -1.380 | -1.640 | -2.420 | -3.360 | -3.330 | -3.038 | -2.414 | -0.4975 |
| Free Cash Flow 1 | - | -28.06 | -49.12 | -79.06 | -76.46 | -138 | -104.9 | -35.51 |
| FCF margin | - | -221.14% | - | - | - | - | -701.69% | -30.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/15/19 | 6/29/20 | 7/13/21 | 7/7/22 | 7/7/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | 0.6907 | 1.036 | 5.979 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.6 | -26.68 | -26.81 | -26.32 | -25.88 | -26.94 | -31.73 | -29.09 | -29.75 | -33.15 | -34.1 | -34.07 | -34.66 | -35.52 | -29.75 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | -5,018.03% | -3,427.29% | -497.54% |
| Earnings before Tax (EBT) 1 | -19.65 | -22.47 | -24.11 | -23.04 | -22.26 | -21.3 | -26.3 | -25.32 | -27.65 | -29.03 | -31.65 | -31.31 | -31.98 | -32.92 | -27.23 |
| Net income 1 | -19.65 | -22.47 | -24.11 | -23.04 | -22.26 | -21.3 | -26.3 | -25.32 | -27.65 | -29.03 | -32.06 | -31.38 | -31.82 | -32.48 | -28.72 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -4,607.27% | -3,133.88% | -480.28% |
| EPS 2 | -0.8000 | -0.9200 | -0.9800 | -0.9400 | -0.9000 | -0.7500 | -0.7700 | -0.7400 | -0.8000 | -0.8400 | -0.7217 | -0.6733 | -0.6767 | -0.6867 | -0.5933 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/9/21 | 3/10/22 | 7/7/22 | 9/8/22 | 12/8/22 | 3/9/23 | 7/7/23 | 9/7/23 | 12/7/23 | 3/11/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 32 | 67.7 | 249 | 166 | 149 | 218 | 105 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -28.1 | -49.1 | -79.1 | -76.5 | -138 | -105 | -35.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.08 | 0.22 | 0.08 | 0.93 | 1.2 | 0.23 | 0.8 | 0.83 |
| Capex / Sales | 6.7% | 1.73% | - | - | - | - | 5.33% | 0.7% |
| Announcement Date | 7/15/19 | 6/29/20 | 7/13/21 | 7/7/22 | 7/7/23 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.88
USD
Average target price
29.8
USD
Spread / Average Target
+150.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.63% | 501M | |
| -3.15% | 89.69B | |
| +2.50% | 41.34B | |
| -12.00% | 33.72B | |
| +62.74% | 26.11B | |
| -20.01% | 14.63B | |
| -8.65% | 12.84B | |
| -12.34% | 11.66B | |
| -43.92% | 11.52B | |
| +4.27% | 8.92B |
- Stock Market
- Equities
- KALV Stock
- Financials KalVista Pharmaceuticals, Inc.